" class="no-js "lang="en-US"> MTA's ECCMID 2023 Highlight Reel
Saturday, June 10, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases

May 8 2023

MTA’s ECCMID 2023 Highlight Reel

The 33rd ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) is a scientific conference that brings together professionals in the field of clinical microbiology and infectious diseases. It is one of the largest and most prominent events of its kind in Europe and features a wide range of presentations, workshops, and exhibits on topics related to infectious diseases, microbiology, and antimicrobial resistance.

The 33rd ECCMID was held from April 15-18, 2023 and was organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and attracted thousands of attendees from around the world.

The MTA team headed to Copenhagen, Denmark to find out more.

  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

    Gene Therapy

     Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

    Diseases

     Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas

    Clinical Trials

     Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

    News

     Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

    Drug Development

     Read more
More On